A Clinical Study to Assess the Effect of a Dietary Supplement on Menstrual Cycle Symptoms

This is a single-group, virtual clinical trial evaluating the effects of a daily dietary supplement (DITTO Cycle Supplement) on menstrual cycle symptoms across three menstrual cycles. The study investigates changes in symptom severity and quality of life through validated questionnaires including the Menstrual Symptoms Questionnaire (MSQ).

Study Overview

• Status: Completed
• Conditions: Menstrual Pain; Premenstrual Syndrome
• Intervention / Treatment: Dietary supplement: DITTO Cycle Supplement

• Study Type: Interventional
• Enrollment (Actual): 40
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Nevada
    • Las Vegas, Nevada, United States, 89118
      • Citruslabs

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Female-at-birth
• Aged 18-45
• In the last three menstrual cycles, has experienced three or more of the following symptoms associated with their menstrual cycle: Menstrual cramps, Bloating, Breast tenderness, Headaches, Fatigue, Muscle aches and/or joint pain, Cravings, Mood swings, Low mood, Feelings of anxiety, Irritability, Difficulty concentrating
• Generally healthy - does not live with any uncontrolled chronic disease
• Has a regular menstrual cycle length, between 23 and 35 days
• Tracks their menstrual cycle and can predict their period dates
• Anyone willing to comply with study requirements
• Anyone with no known allergies to the ingredients listed in the product

Exclusion Criteria:

• Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders
• Women who are pregnant, breastfeeding, or trying to conceive
• Anyone unwilling to follow the study protocol
• Anyone in perimenopause, menopause, or experiencing menopausal-type symptoms
• Anyone with planned surgery during the study period
• Anyone with a history of substance abuse
• Anyone diagnosed with high blood pressure, high cholesterol, heart disease, heart attack, stroke, irregular heartbeat (AFib), clogged arteries, poor circulation, heart failure, or other heart conditions
• Anyone diagnosed with a hormone or reproductive health-related cancer or benign condition
• Anyone diagnosed with a menstrual health condition such as endometriosis, PCOS, or adenomyosis
• Anyone diagnosed with diabetes or other endocrine-related condition
• Anyone currently participating or planning to participate in a research study
• Anyone who has started, changed, or stopped taking hormonal birth control in the last three months
• Has a planned insertion or replacement of an IUD in the next 12 weeks

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DITTO Cycle Supplement; Participants will take two capsules of the DITTO Cycle Supplement once daily, starting two days after menstrual bleeding ends, for the duration of three menstrual cycles.	Dietary supplement: DITTO Cycle Supplement; The capsules should be taken in the morning with the first meal and a glass of water.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Menstrual Symptoms Questionnaire (MSQ) Scores	Change from baseline in menstrual symptom severity as measured by the Menstrual Symptoms Questionnaire (MSQ), including cramps, bloating, fatigue, mood swings, breast tenderness, headaches, anxiety, irritability, and difficulty concentrating.	Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Menstrual-Related Quality of Life	Change from baseline in participant-reported quality of life related to menstrual symptoms, measured using study-specific self-report questionnaires evaluating overall impact on daily living and well-being.	Baseline, End of Cycle 1(28 days), End of Cycle 2(28 days), End of Cycle 3 (28 days)

Collaborators and Investigators

• Sponsor: Muse Nutrition Ltd
• Collaborators: Citruslabs

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2025
• Primary Completion (Actual): July 1, 2025
• Study Completion (Actual): July 1, 2025

Study Registration Dates

• First Submitted: November 19, 2025
• First Submitted That Met QC Criteria: November 25, 2025
• First Posted (Actual): December 5, 2025

Study Record Updates

• Last Update Posted (Actual): December 5, 2025
• Last Update Submitted That Met QC Criteria: November 25, 2025
• Last Verified: November 1, 2025

More Information

Terms related to this study

• Keywords: Mood Disorders; Bloating
• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Mental Disorders; Pathologic Processes; Pelvic Pain; Menstruation Disturbances; Pathological Conditions, Signs and Symptoms; Signs and Symptoms; Mood Disorders; Premenstrual Syndrome; Dysmenorrhea
• Other Study ID Numbers: 20736

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No